News

 

 

Funding: New Awards

Frederick Lansigan, MD
Assistant Professor
Molecular Therapeutics

  • Novartis Pharmaceuticals
    A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-Chemotherapy

Margit McGowan, DO
Assistant Professor
Molecular Therapeutics

  • ECOG
    A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion